HCW Biologics

HCWB41

Penny Stock

$0.64arrow_drop_up5.05%$0.03

Penny Stock

HCWB41

$0.64

arrow_drop_up5.05%$0.03

Penny Stock

Performance History

Key Stats
Open	$0.68
Prev. Close	$0.61
EPS	-1.05
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$23.18M
PE Ratio	-

	LOW	HIGH
Day Range	0.64	0.68
52 Week Range	0.40	2.16

Ratios







EPS	-1.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About HCW Biologics (HCWB)

HCW Biologics Inc. (HCWB) is a biotechnology company that specializes in the development and commercialization of innovative biologic products. The company is committed to advancing the field of biotechnology and improving patient outcomes through its cutting-edge research and development efforts. HCWB is focused on the discovery and development of novel therapeutics for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

One of the key strengths of HCW Biologics Inc. is its advanced manufacturing capabilities. The company utilizes state-of-the-art bioprocessing techniques to produce high-quality biologic products at scale. This allows HCWB to meet the growing demand for biologic therapies and ensures consistent supply to patients in need. Additionally, HCWB's manufacturing processes are designed to comply with regulatory standards, ensuring the safety and efficacy of its products.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Hing C. Wong Ph.D.
Headquarters: Miramar
Employees: 44
Exchange: NASDAQ

Keep an eye on HCW Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is HCW Biologics's (HCWB) price per share?

The current price per share for HCW Biologics (HCWB) is $0.64. The stock has seen a price change of $0.03 recently, indicating a 5.06% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for HCW Biologics (HCWB)?

For HCW Biologics (HCWB), the 52-week high is $2.17, which is 236.34% from the current price. The 52-week low is $0.4, the current price is 61% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is HCW Biologics (HCWB) a growth stock?

HCW Biologics (HCWB) has shown an average price growth of 0.41% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying HCW Biologics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is HCW Biologics (HCWB) stock price performance year to date (YTD)?

As of the latest data, HCW Biologics (HCWB) has a year-to-date price change of -46.33%. Over the past month, the stock has experienced a price change of 52.97%. Over the last three months, the change has been -19.52%. Over the past six months, the figure is -63.2%.

help

Is HCW Biologics (HCWB) a profitable company?

HCW Biologics (HCWB) has a net income of -$24.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.24K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.84M, although specific revenue growth data is currently not available. Operating income is noted at -$25.72M. Furthermore, the EBITDA is -$36.58M.

help

What is the market capitalization of HCW Biologics (HCWB)?

HCW Biologics (HCWB) has a market capitalization of $23.19M. The average daily trading volume is 17.6K, indicating the stock's liquidity and investor engagement.

News

FDA Inspection Preparedness and Compliance Seminar: Information and for Tools Pharmaceutical, Biopharmaceutical, Biologics and Medical Device Professionals | ON-DEMAND

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction